(NVST) Envista Holdings - Overview
Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: NYSE (USA) | Market Cap: 4.371m USD | Total Return: 69.8% in 12m
Dental Implants, Orthodontics, Dental Equipment, Dental Materials
Total Rating 68
Safety 69
Buy Signal -0.22
Medical Instruments & Supplies
Industry Rotation: -3.2
Industry Rotation: -3.2
Market Cap:
4.37B
Avg Turnover: 57.1M USD
Avg Turnover: 57.1M USD
ATR:
4.14%
Peers RS (IBD): 87.5
Peers RS (IBD): 87.5
Risk 5d forecast
Volatility38.8%
Rel. Tail Risk-8.30%
Reward TTM
Sharpe Ratio1.27
Alpha16.23
Character TTM
Beta1.706
Beta Downside2.101
Drawdowns 3y
Max DD62.29%
CAGR/Max DD-0.18
EPS (Earnings per Share)
EPS CAGR: -5.51%
EPS Trend: -56.1%
EPS Trend: -56.1%
Last SUE: 0.78
Qual. Beats: 0
Qual. Beats: 0
Revenue
Rev. CAGR: 4.72%
Rev. Trend: 41.8%
Rev. Trend: 41.8%
Last SUE: 4.00
Qual. Beats: 4
Qual. Beats: 4
Warnings
P/E ratio 95.2
Tailwinds
No distinct edge detected
Description: NVST Envista Holdings
Envista Holdings Corporation (NVST) is a global dental products manufacturer. The company operates in the Health Care Equipment sector, which is characterized by ongoing innovation in dental technologies and materials.
The company has two primary segments. The Specialty Products & Technologies segment focuses on dental implant systems, biomaterials, prosthetics, and orthodontic products, including clear aligners. These products are sold to dental specialists and general dentists.
The Equipment & Consumables segment provides digital imaging systems, endodontic products, restorative materials, and infection prevention supplies. This segment serves dental offices, clinics, and hospitals.
Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California. To understand the companys market position, further research on its competitive landscape and product differentiation on ValueRay would be beneficial.
- Dental implant demand drives Specialty Products revenue
- Orthodontic clear aligner adoption boosts sales growth
- Equipment and consumables sales depend on dental office visits
- Regulatory changes impact dental product approval timelines
- Healthcare spending trends influence elective dental procedures
Piotroski VR‑10 (Strict)
6.5
| Net Income: 47.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -1.60 > 1.0 |
| NWC/Revenue: 43.17% < 20% (prev 36.23%; Δ 6.94% < -1%) |
| CFO/TA 0.05 > 3% & CFO 275.7m > Net Income 47.0m |
| Net Debt (496.4m) to EBITDA (354.1m): 1.40 < 3 |
| Current Ratio: 2.38 > 1.5 & < 3 |
| Outstanding Shares: last quarter (166.0m) vs 12m ago -3.60% < -2% |
| Gross Margin: 54.95% > 18% (prev 0.55%; Δ 5.44k% > 0.5%) |
| Asset Turnover: 49.31% > 50% (prev 46.92%; Δ 2.39% > 0%) |
| Interest Coverage Ratio: 6.28 > 6 (EBITDA TTM 354.1m / Interest Expense TTM 36.6m) |
Altman Z''
1.16
| A: 0.21 (Total Current Assets 2.03b - Total Current Liabilities 852.6m) / Total Assets 5.68b |
| B: -0.08 (Retained Earnings -440.4m / Total Assets 5.68b) |
| C: 0.04 (EBIT TTM 229.7m / Avg Total Assets 5.51b) |
| D: -0.21 (Book Value of Equity -551.8m / Total Liabilities 2.57b) |
| Altman-Z'' Score: 1.16 = BB |
Beneish M
-2.95
| DSRI: 1.09 (Receivables 429.6m/363.0m, Revenue 2.72b/2.51b) |
| GMI: 1.00 (GM 54.95% / 54.91%) |
| AQI: 0.96 (AQ_t 0.57 / AQ_t-1 0.59) |
| SGI: 1.08 (Revenue 2.72b / 2.51b) |
| TATA: -0.04 (NI 47.0m - CFO 275.7m) / TA 5.68b) |
| Beneish M-Score: -2.95 (Cap -4..+1) = A |
What is the price of NVST shares?
As of April 12, 2026, the stock is trading at USD 26.39 with a total of 1,181,486 shares traded.
Over the past week, the price has changed by +2.25%, over one month by +1.50%, over three months by +12.87% and over the past year by +69.82%.
Over the past week, the price has changed by +2.25%, over one month by +1.50%, over three months by +12.87% and over the past year by +69.82%.
Is NVST a buy, sell or hold?
Envista Holdings has received a consensus analysts rating of 3.29.
Therefor, it is recommend to hold NVST.
- StrongBuy: 3
- Buy: 0
- Hold: 10
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the NVST price?
| Analysts Target Price | 28.5 | 8% |
Envista Holdings (NVST) - Fundamental Data Overview
as of 11 April 2026
P/E Trailing = 95.25 P/E Forward = 20.3252
P/S = 1.6071
P/B = 1.3616
Revenue TTM = 2.72b USD
EBIT TTM = 229.7m USD
EBITDA TTM = 354.1m USD
Long Term Debt = 1.45b USD (from longTermDebt, last quarter)
Short Term Debt = 39.0m USD (from shortTermDebt, last quarter)
Debt = 1.71b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 496.4m USD (from netDebt column, last quarter)
Enterprise Value = 4.87b USD (4.37b + Debt 1.71b - CCE 1.21b)
Interest Coverage Ratio = 6.28 (Ebit TTM 229.7m / Interest Expense TTM 36.6m)
EV/FCF = 21.12x (Enterprise Value 4.87b / FCF TTM 230.4m)
FCF Yield = 4.73% (FCF TTM 230.4m / Enterprise Value 4.87b)
FCF Margin = 8.47% (FCF TTM 230.4m / Revenue TTM 2.72b)
Net Margin = 1.73% (Net Income TTM 47.0m / Revenue TTM 2.72b)
Gross Margin = 54.95% ((Revenue TTM 2.72b - Cost of Revenue TTM 1.23b) / Revenue TTM)
Gross Margin QoQ = 55.04% (prev 55.99%)
Tobins Q-Ratio = 0.86 (Enterprise Value 4.87b / Total Assets 5.68b)
Interest Expense / Debt = 0.60% (Interest Expense 10.3m / Debt 1.71b)
Taxrate = 42.88% (24.7m / 57.6m)
NOPAT = 131.2m (EBIT 229.7m * (1 - 42.88%))
Current Ratio = 2.38 (Total Current Assets 2.03b / Total Current Liabilities 852.6m)
Debt / Equity = 0.55 (Debt 1.71b / totalStockholderEquity, last quarter 3.11b)
Debt / EBITDA = 1.40 (Net Debt 496.4m / EBITDA 354.1m)
Debt / FCF = 2.15 (Net Debt 496.4m / FCF TTM 230.4m)
Total Stockholder Equity = 3.09b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.85% (Net Income 47.0m / Total Assets 5.68b)
RoE = 1.52% (Net Income TTM 47.0m / Total Stockholder Equity 3.09b)
RoCE = 5.06% (EBIT 229.7m / Capital Employed (Equity 3.09b + L.T.Debt 1.45b))
RoIC = 2.90% (NOPAT 131.2m / Invested Capital 4.53b)
WACC = 8.71% (E(4.37b)/V(6.08b) * Re(11.98%) + D(1.71b)/V(6.08b) * Rd(0.60%) * (1-Tc(0.43)))
Discount Rate = 11.98% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -1.67%
[DCF] Terminal Value 77.61% ; FCFF base≈259.3m ; Y1≈290.8m ; Y5≈388.0m
[DCF] Fair Price = 33.40 (EV 5.94b - Net Debt 496.4m = Equity 5.44b / Shares 163.0m; r=8.71% [WACC]; 5y FCF grow 14.07% → 3.0% )
EPS Correlation: -56.13 | EPS CAGR: -5.51% | SUE: 0.78 | # QB: 0
Revenue Correlation: 41.78 | Revenue CAGR: 4.72% | SUE: 4.0 | # QB: 4
EPS next Quarter (2026-06-30): EPS=0.32 | Chg7d=-0.004 | Chg30d=-0.005 | Revisions Net=-1 | Analysts=13
EPS current Year (2026-12-31): EPS=1.41 | Chg7d=-0.001 | Chg30d=+0.000 | Revisions Net=-1 | Growth EPS=+18.5% | Growth Revenue=+4.6%
EPS next Year (2027-12-31): EPS=1.56 | Chg7d=-0.002 | Chg30d=+0.001 | Revisions Net=-1 | Growth EPS=+10.5% | Growth Revenue=+3.6%
[Analyst] Revisions Ratio: -1.00 (0 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 10.9% (Discount Rate 12.0% - Earnings Yield 1.0%)
[Growth] Growth Spread = -6.2% (Analyst 4.8% - Implied 10.9%)
External Resources